8-K: Achieve Life Sciences Announces Positive Q2 Results and Breakthrough Therapy Designation for Vaping Cessation

Achieve Life Sciences reported its second quarter 2024 financial results, highlighted by FDA Breakthrough Therapy designation for cytisinicline in vaping cessation and a loan refinancing.

Summary

• Achieve Life Sciences announced its financial results for the second quarter of 2024, with a net loss of $8.5 million for the quarter and $15.0 million for the first six months of the year.
• The company's cash, cash equivalents, and short-term investments totaled $61.3 million as of June 30, 2024.
• The FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette cessation, which aims to expedite the development and review process.
• Achieve refinanced its debt with Silicon Valley Bank, extending the maturity date to December 1, 2027, and securing up to $20 million.
• The company was included in the U.S. Russell 3000 and Russell Microcap Indexes, effective July 1, 2024.
• The ORCA-OL clinical trial, evaluating long-term cytisinicline exposure, was initiated in May 2024, with over half of the 650 planned participants already enrolled.
• Data from the ORCA-V1 trial showed cytisinicline more than doubled the likelihood of quitting e-cigarettes compared to placebo.
• Achieve anticipates submitting a New Drug Application (NDA) in the first half of 2025.

Sentiment

Score: 8

Explanation: The document is very positive due to the Breakthrough Therapy designation, successful debt refinancing, and promising clinical trial results. The company is making good progress towards its goals, although it is still loss-making.

Positives

• The FDA's Breakthrough Therapy designation for cytisinicline in vaping cessation is a significant regulatory milestone.
• The successful debt refinancing with Silicon Valley Bank provides financial stability and extends the loan maturity.
• Inclusion in the Russell 3000 and Russell Microcap Indexes increases the company's visibility and potential investor base.
• The ORCA-OL trial is progressing well with strong enrollment, supporting the NDA submission timeline.
• The ORCA-V1 data showing a doubling of e-cigarette cessation rates compared to placebo is very promising.
• The company has a strong cash position of $61.3 million.

Negatives

• The company reported a net loss of $8.5 million for the second quarter of 2024 and $15.0 million for the first six months of the year.
• The company is still in the development stage and is not yet generating revenue from product sales.

Risks

• The development of cytisinicline is subject to regulatory approval, and there is no guarantee that it will be approved.
• The company may need to raise additional capital to fund its operations and clinical trials.
• There are risks associated with the commercialization of cytisinicline, including market acceptance and competition.
• The company's intellectual property may not be adequately protected.
• Macroeconomic and geopolitical factors could impact the business.

Future Outlook

Achieve anticipates submitting a New Drug Application (NDA) for cytisinicline in the first half of 2025.

Management Comments

• John Bencich, Chief Executive Officer, stated that they are extremely proud of the significant milestones achieved, including the Breakthrough Therapy designation for vaping cessation.
• John Bencich also noted that they are making great progress in the ORCA-OL trial, moving them closer to their expected NDA filing in the first half of 2025.

Industry Context

The announcement is significant given the growing concern over nicotine addiction, particularly vaping, and the lack of FDA-approved treatments specifically for vaping cessation. Achieve's progress positions them as a potential leader in this space.

Comparison to Industry Standards

• The Breakthrough Therapy designation is a significant advantage, as it aims to accelerate the development and review process, which is faster than standard drug approvals.
• The ORCA-V1 trial results, showing a doubling of e-cigarette cessation rates compared to placebo, are competitive with other smoking cessation treatments.
• The company's cash position of $61.3 million is relatively strong for a company at this stage of development, providing a runway for further clinical trials and regulatory submissions.
• Compared to companies like Pfizer (with Chantix) and Johnson & Johnson (with Nicorette), Achieve is focused on a novel plant-based treatment and is specifically targeting the vaping cessation market, which is a growing area of unmet need.

Stakeholder Impact

• Shareholders will benefit from the positive news, including the Breakthrough Therapy designation and debt refinancing.
• Employees will be encouraged by the company's progress and future prospects.
• Customers (potential patients) will have access to a new treatment option for nicotine addiction.
• Creditors will be reassured by the company's financial stability and extended loan maturity.

Next Steps

• Achieve plans to hold an End-of-Phase 2 meeting with the FDA before the end of the year.
• The company will continue enrollment in the ORCA-OL trial.
• Achieve anticipates submitting a New Drug Application (NDA) in the first half of 2025.

Key Dates

Keywords

cytisinicline, smoking cessation, vaping cessation, nicotine addiction, FDA, Breakthrough Therapy designation, clinical trials, ORCA-OL, ORCA-V1, debt refinancing, Russell 3000, Russell Microcap, pharmaceutical